Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04113018 · OUTCOME

Daratumumab Administration - Number of Doses Received

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma · Source last updated 2026-08-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
count of doses
Interval / dispersion
Full Range
Time frame
From enrollment to completion of induction; evaluated for approximately 32 weeks (8 28-day cycles).

What was measured

Descriptive summary of daratumumab administration. Number of doses of daratumumab received.

Analysis population: The evaluable population is defined as all subjects who initiate treatment with daratumumab

Groups in this outcome

KRd-Daratumumab

Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab: Experimental

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
KRd-Daratumumab39

Reported measurements

Source class 1
Values in count of doses · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
KRd-Daratumumab17Not reported119Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        19
        value
        17
denoms
  1. counts
    1. group Id
      OG000
      value
      39
    units
    Participants
description
Descriptive summary of daratumumab administration. Number of doses of daratumumab received.
dispersion Type
Full Range
groups
  1. description
    Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab: Experimental
    id
    OG000
    title
    KRd-Daratumumab
param Type
MEDIAN
population Description
The evaluable population is defined as all subjects who initiate treatment with daratumumab
reporting Status
POSTED
time Frame
From enrollment to completion of induction; evaluated for approximately 32 weeks (8 28-day cycles).
title
Daratumumab Administration - Number of Doses Received
type
OTHER_PRE_SPECIFIED
unit Of Measure
count of doses

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice